AstraZeneca Pharma India · NSE: ASTRAZEN · BSE: 506820
Q1 FY27 results · Apr–Jun 2026
AstraZeneca Pharma India reported revenue from operations of ₹682.79 crore (up 29.7% from Q1 FY26) and net profit of ₹37.93 crore (down 32.1% from Q1 FY26) for Q1 FY27 (Apr–Jun 2026), on a standalone basis.
| Item | Q1 FY27 | Q1 FY26 | YoY | Q4 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 682.79 | 526.31 | +29.7% | 578.61 | +18.0% |
| Other income | 9.23 | 11.24 | −17.9% | 5.95 | +55.1% |
| Total income | 692.02 | 537.55 | +28.7% | 584.56 | +18.4% |
| Profit before tax | 50.75 | 74.70 | −32.1% | 58.14 | −12.7% |
| Net profit for the period | 37.93 | 55.83 | −32.1% | 44.88 | −15.5% |
| EPS, basic (₹) | 15.17 | 22.33 | −32.1% | 17.95 | −15.5% |
| Net margin (%) | 5.6 | 10.6 | 7.8 |
Standalone
- Filed with BSE
- 11 Aug 2026, 12:55 IST
- Board meeting
- 10 Aug 2026
- Period
- 01 Apr 2026 to 30 Jun 2026
- Review status
- Unaudited
- Source
- XBRL filing on BSE